147 related articles for article (PubMed ID: 20450295)
1. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.
Martínez-González J; Rodríguez C
Expert Rev Cardiovasc Ther; 2010 May; 8(5):625-34. PubMed ID: 20450295
[TBL] [Abstract][Full Text] [Related]
2. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
Martínez-González J; Vila L; Rodríguez C
Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
[TBL] [Abstract][Full Text] [Related]
3. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
4. Bemiparin, an effective and safe low molecular weight heparin: a review.
Ciccone MM; Cortese F; Corbo F; Corrales NE; Al-Momen AK; Silva A; Zito A; Pinto M; Gesualdo M; Scicchitano P
Vascul Pharmacol; 2014 Jul; 62(1):32-7. PubMed ID: 24657810
[TBL] [Abstract][Full Text] [Related]
5. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
[TBL] [Abstract][Full Text] [Related]
6. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.
Chapman TM; Goa KL
Drugs; 2003; 63(21):2357-77. PubMed ID: 14524738
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Santamaría A; Juárez S; Reche A; Gómez-Outes A; Martínez-González J; Fontcuberta J;
Int J Clin Pract; 2006 May; 60(5):518-25. PubMed ID: 16700847
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
Otero-Fernández R; Gómez-Outes A; Martínez-González J; Rocha E; Fontcuberta J;
Clin Appl Thromb Hemost; 2008 Jan; 14(1):75-83. PubMed ID: 17895506
[TBL] [Abstract][Full Text] [Related]
9. Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism.
Planès A
Expert Opin Pharmacother; 2003 Sep; 4(9):1551-61. PubMed ID: 12943485
[TBL] [Abstract][Full Text] [Related]
10. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
11. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
[TBL] [Abstract][Full Text] [Related]
12. Bemiparin: pharmacological profile.
Sánchez-Ferrer CF
Drugs; 2010 Dec; 70 Suppl 2():19-23. PubMed ID: 21162606
[TBL] [Abstract][Full Text] [Related]
13. Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients.
Farge D; Durant C; Villiers S; Long A; Mahr A; Marty M; Debourdeau P;
Thromb Res; 2010 Apr; 125 Suppl 2():S108-16. PubMed ID: 20433988
[TBL] [Abstract][Full Text] [Related]
14. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
15. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
16. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
17. Heparin and low molecular weight heparin in thrombosis and beyond.
Mousa SA
Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
[TBL] [Abstract][Full Text] [Related]
18. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
[TBL] [Abstract][Full Text] [Related]
19. Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations.
Dalmora SL; Junior LB; Vaccari SF; Fronza M; Renato de Oliveira P; Rolim CM
Farmaco; 2005 Mar; 60(3):225-9. PubMed ID: 15784241
[TBL] [Abstract][Full Text] [Related]
20. Prevention of deep vein thrombosis in cancer patients.
Lee AY
Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
